Through this rule, FDA is updating the standards for FDA acceptance of data from clinical investigations conducted outside the United States to help ensure the quality and integrity of data obtained from these investigations and the protection of human subjects. In this rule, FDA is amending the regulations for PMA applications, HDE applications, IDE applications, and premarket notification submissions. As part of this rule, FDA also is amending the IDE regulations and the premarket notification regulations to address the requirements for FDA acceptance of data from clinical investigations conducted inside the United States.
News & Trends
- GDP Nível 2 : Mais uma edição marcada pelo sucesso em termos de utilidade e relevancia para os formandos
- CAPAS 2024 : “Exemplos excelentes e significativos vs legislação e teoria. Bem explicados!
- Novos catálogos eletrónicos HMA-EMA de fontes de dados do mundo real e estudos
- Medical devices: Council endorses new measures to help prevent shortages
- Charging for Investigational Drugs Under an IND: Questions and Answers
- FDA final rule to amend the device current good manufacturing practice requirements to harmonize and modernize the regulation
- EUDAMED user guide Economic Operators – Actor module
- Portaria n.º 51/2024, de 15 de fevereiro : Regras de formatação das informações obrigatórias sobre o preços dos medicamentos